Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Stroke. 2016 Jun 28;47(8):2096–2102. doi: 10.1161/STROKEAHA.116.012678

Figure 3.

Figure 3

CSF cAMP and phosphorylated p38 MAPK prior to thrombotic stroke (sham control), after stroke (PTI), or treated at 4h post injury with wt-tPA (1 mg/kg iv), tPA-A296-299 (1 mg/kg iv), tPA-A296-299 + IgG (10 μg/ml), tPA-A296-299+ anti LRP Ab (10 μg/ml), or tPA-A296-299 + RAP (10−7 M), n=5. *p<0.05 versus corresponding sham control value +p<0.05 versus corresponding untreated PTI value #p<0.05 versus tPA-A296-299 alone.